Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurodegenerative diseases
Biotech
AAIC: Roche ‘very interested’ in tau despite amyloid AD focus
Roche’s biggest bet in Alzheimer’s may be its phase 3-stage amyloid asset, but the pharma is keeping its options open when it comes to targeting tau.
James Waldron
Jul 15, 2026 8:42am
Study shows promise of brain interface training for patients
Jul 15, 2026 3:00am
Fierce Pharma
Fosun Pharma plots global push, fueled by Alzheimer’s deals
Jun 25, 2026 7:00pm
Insilico lands backloaded $2.5B AI deal with SK Biopharm
Jun 22, 2026 12:30am
Novartis ‘always looking’ for new ways to shuttle drugs to brain
May 28, 2026 8:44am
NeuroVision acquires fellow dx player Durin Life Sciences
May 15, 2026 7:47am
